Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Original Article

Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease

Jean-Guillaume Dillinger, Vincent Maher, Cristiana Vitale, Patrick Henry, Damien Logeart, Stephane Manzo Silberman, Guillaume Allée, Bernard I. Levy
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.115.06091
Hypertension. 2015;HYPERTENSIONAHA.115.06091
Originally published September 21, 2015
Jean-Guillaume Dillinger
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Maher
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristiana Vitale
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Henry
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damien Logeart
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephane Manzo Silberman
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Allée
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard I. Levy
From the Service de Cardiologie, Hôpital Lariboisière, Paris, France (J.-G.D., P.H., D.L., S.M.S.); Adipose Vascular Research Unit, Adelaide and Meath Hospital, Dublin, Ireland (V.M.); Department of Medical Science, IRCCS San Raffaele Pisana, Rome, Italy (C.V.); Institut de Recherches Internationales Servier, Cardiovascular Therapeutic Innovation Pole, Suresnes, France (G.A.); and Physiologie Clinique, Explorations Fonctionnelles, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France (B.I.L.); Inserm U970, PARRC HEGP, Paris, France (B.I.L.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Treatment of hypertensive patients with β-blockers reduces heart rate and decreases central blood pressure less than other antihypertensive drugs, implying that reducing heart rate without altering brachial blood pressure could increase central blood pressure, explaining the increased cardiovascular risk reported with β-blocker. We describe a randomized, double-blind study to explore whether heart rate reduction with the If inhibitor ivabradine had an impact on central blood pressure. We included 12 normotensive patients with stable coronary artery disease, heart rate ≥70 bpm (sinus rhythm), and stable background β-blocker therapy. Patients received ivabradine 7.5 mg BID or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting heart rate after 3 weeks versus no change with placebo (−15.8±7.7 versus +0.3±5.8 bpm; P=0.0010). There was no relevant between-group difference in change in central aortic systolic blood pressure (−4.0±9.6 versus +2.4±12.0 mm Hg; P=0.13) or augmentation index (−0.8±10.0% versus +0.3±7.6%; P=0.87). Treatment with ivabradine was associated with a modest increase in left ventricular ejection time (+18.5±17.8 versus +2.8±19.3 ms; P=0.074) and a prolongation of diastolic perfusion time (+215.6±105.3 versus −3.0±55.8 ms with placebo; P=0.0005). Consequently, ivabradine induced a pronounced increase in Buckberg index, an index of myocardial viability (+39.3±27.6% versus −2.5±13.5% with placebo; P=0.0015). In conclusion, heart rate reduction with ivabradine does not increase central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion index.

Clinical Trial Registration—URL: https://www.clinicaltrialsregister.eu. Unique identifier: 2011-004779-35.

  • blood pressure
  • cardiovascular diseases
  • coronary artery disease
  • heart rate
  • ivabradine
  • Received July 2, 2015.
  • Revision received July 14, 2015.
  • Accepted September 4, 2015.
  • © 2015 American Heart Association, Inc.
Back to top
Next Article

Current Issue

Hypertension
May 2018, Volume 71, Issue 5
  • Table of Contents
Next Article

Jump to

  • Article
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease
    Jean-Guillaume Dillinger, Vincent Maher, Cristiana Vitale, Patrick Henry, Damien Logeart, Stephane Manzo Silberman, Guillaume Allée and Bernard I. Levy
    Hypertension. 2015;HYPERTENSIONAHA.115.06091, originally published September 21, 2015
    https://doi.org/10.1161/HYPERTENSIONAHA.115.06091

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease
    Jean-Guillaume Dillinger, Vincent Maher, Cristiana Vitale, Patrick Henry, Damien Logeart, Stephane Manzo Silberman, Guillaume Allée and Bernard I. Levy
    Hypertension. 2015;HYPERTENSIONAHA.115.06091, originally published September 21, 2015
    https://doi.org/10.1161/HYPERTENSIONAHA.115.06091
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Intervention, Surgery, Transplantation
    • Pharmacology
  • Basic, Translational, and Clinical Research
    • Clinical Studies
    • Hemodynamics

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured